Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC (Hiltonol) Prior to Radical Prostatectomy in Prostate Cancer
NCT03262103Phase 1Completed
- Start
- Jun 2017
- Primary completion
- May 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of poly iclc in prostate cancer (PCa) (4 cohorts). Primary endpoint: Dose-Limiting Toxicity level at 6 weeks. Started Jun 2017; status: completed.
02
Drugs
poly iclc
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03262103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262103.